pioglitazone has been researched along with ALS - Amyotrophic Lateral Sclerosis in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS)." | 9.16 | A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. ( Benecke, R; Bogdahn, U; Dengler, R; Dreyhaupt, J; Dupuis, L; Fischer, W; Grehl, T; Grosskreutz, J; Heneka, MT; Hermann, A; Kassubek, J; Lindauer, E; Ludolph, AC; Meyer, T; Otto, M; Schrank, B; Steiner, F; Wessig, C; Winkler, AS; Zierz, S, 2012) |
| " Herein, we have studied the potential of nanomedicine to prepare a single platform based on mesoporous silica nanoparticles (MSNs) for the treatment of an ALS animal model with a cocktail of agents such as leptin (neuroprotective) and pioglitazone (anti-inflammatory), which have already demonstrated promising therapeutic ability in other neurodegenerative diseases." | 8.12 | Design of Mesoporous Silica Nanoparticles for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with a Therapeutic Cocktail Based on Leptin and Pioglitazone. ( Cabrera-Pinto, M; Díaz-García, D; Díaz-Sánchez, M; Fernandez-Martos, CM; Ferrer-Donato, Á; Gómez-Ruiz, S; Méndez-Arriaga, JM; Prashar, S, 2022) |
| "Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS)." | 5.16 | A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. ( Benecke, R; Bogdahn, U; Dengler, R; Dreyhaupt, J; Dupuis, L; Fischer, W; Grehl, T; Grosskreutz, J; Heneka, MT; Hermann, A; Kassubek, J; Lindauer, E; Ludolph, AC; Meyer, T; Otto, M; Schrank, B; Steiner, F; Wessig, C; Winkler, AS; Zierz, S, 2012) |
| " Herein, we have studied the potential of nanomedicine to prepare a single platform based on mesoporous silica nanoparticles (MSNs) for the treatment of an ALS animal model with a cocktail of agents such as leptin (neuroprotective) and pioglitazone (anti-inflammatory), which have already demonstrated promising therapeutic ability in other neurodegenerative diseases." | 4.12 | Design of Mesoporous Silica Nanoparticles for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with a Therapeutic Cocktail Based on Leptin and Pioglitazone. ( Cabrera-Pinto, M; Díaz-García, D; Díaz-Sánchez, M; Fernandez-Martos, CM; Ferrer-Donato, Á; Gómez-Ruiz, S; Méndez-Arriaga, JM; Prashar, S, 2022) |
| "Pioglitazone treatment extended survival by 13%, and it reduced gliosis as assessed by immunohistochemical staining for CD-40 and GFAP." | 1.33 | Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Chen, J; Kiaei, M; Kipiani, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Díaz-García, D | 1 |
| Ferrer-Donato, Á | 1 |
| Méndez-Arriaga, JM | 1 |
| Cabrera-Pinto, M | 1 |
| Díaz-Sánchez, M | 1 |
| Prashar, S | 1 |
| Fernandez-Martos, CM | 1 |
| Gómez-Ruiz, S | 1 |
| Jawaid, A | 1 |
| Paganoni, S | 1 |
| Hauser, C | 1 |
| Schulz, PE | 1 |
| Joardar, A | 1 |
| Menzl, J | 1 |
| Podolsky, TC | 1 |
| Manzo, E | 1 |
| Estes, PS | 1 |
| Ashford, S | 1 |
| Zarnescu, DC | 1 |
| Vercruysse, P | 1 |
| Sinniger, J | 1 |
| El Oussini, H | 1 |
| Scekic-Zahirovic, J | 1 |
| Dieterlé, S | 1 |
| Dengler, R | 2 |
| Meyer, T | 2 |
| Zierz, S | 2 |
| Kassubek, J | 2 |
| Fischer, W | 2 |
| Dreyhaupt, J | 2 |
| Grehl, T | 2 |
| Hermann, A | 2 |
| Grosskreutz, J | 2 |
| Witting, A | 1 |
| Van Den Bosch, L | 1 |
| Spreux-Varoquaux, O | 1 |
| Ludolph, AC | 2 |
| Dupuis, L | 2 |
| Shibata, N | 2 |
| Yamamoto, T | 2 |
| Hiroi, A | 1 |
| Omi, Y | 1 |
| Kato, Y | 1 |
| Kobayashi, M | 2 |
| Heneka, MT | 2 |
| Steiner, F | 1 |
| Lindauer, E | 1 |
| Otto, M | 1 |
| Winkler, AS | 1 |
| Bogdahn, U | 1 |
| Benecke, R | 1 |
| Schrank, B | 1 |
| Wessig, C | 1 |
| Kiaei, M | 1 |
| Kipiani, K | 1 |
| Chen, J | 1 |
| Calingasan, NY | 1 |
| Beal, MF | 1 |
| Schütz, B | 1 |
| Reimann, J | 1 |
| Dumitrescu-Ozimek, L | 1 |
| Kappes-Horn, K | 1 |
| Landreth, GE | 1 |
| Schürmann, B | 1 |
| Zimmer, A | 1 |
| Kawaguchi-Niida, M | 1 |
| Toi, S | 1 |
| Hirano, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)[NCT00690118] | Phase 2 | 219 participants (Actual) | Interventional | 2008-05-31 | Terminated (stopped due to The interim analysis showed no tendency in favour of the verum group. Therefore it was decided to stop the study prematurely.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Trials of antidiabetic drugs in amyotrophic lateral sclerosis: proceed with caution?
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Humans; Hypoglycemic Agents; Pioglitazone; | 2014 |
2 trials available for pioglitazone and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Female; Humans; Hypothalamus; Male; Mice; Mice, Inbred C57BL | 2016 |
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Disease-Free Survival; Double-Blind M | 2012 |
6 other studies available for pioglitazone and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Design of Mesoporous Silica Nanoparticles for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with a Therapeutic Cocktail Based on Leptin and Pioglitazone.
Topics: Amyotrophic Lateral Sclerosis; Animals; DNA-Binding Proteins; Leptin; Mice; Mice, Transgenic; Nanopa | 2022 |
PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA-Binding Proteins; Drosophila; Dr | 2015 |
Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Enzyme Activation; Humans; Immunoblo | 2010 |
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Animals; Cell Count; Disease Models, Animal; Di | 2005 |
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Animals; Humans; Hypoglycemic Agents; Male; Mic | 2005 |
Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Blotting, Western; Calcium-Binding | 2008 |